Lisata Therapeutics, Inc.
LSTA
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trialā¦ read more
Healthcare
Biotechnology
27 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.99
Price-3.88%
-$0.04
1Y
Price
Market Cap
$9.015m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$170k
+7.0%
1y CAGR+2.3%
3y CAGR+1.8%
5y CAGREarnings
-$16.351m
+8.7%
1y CAGR+24.8%
3y CAGR-5.8%
5y CAGREPS
-$1.86
+11.3%
1y CAGR+31.2%
3y CAGR+13.3%
5y CAGRBook Value
$10.672m
$14.059m
Assets$3.387m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$13.658m
+10.7%
1y CAGR+6.9%
3y CAGR+6.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company